Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial

A new personalized mRNA vaccine for melanoma is being hailed by some oncologists as a major breakthrough after it reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a late-stage clinical trial.
Dr. Robert Vonderheide, director of Penn Medicine’s Abramson Cancer Center and president-elect of the American Association for Cancer Research, said the results are a “game changer.”
“It will be seen as the first step toward using cancer vaccines to their full potential,” said Vonderheide, who was not involved in the trial.
Opens NBC News in a new tab